Re: Christian Walter, Bilal Al-Nawas, Knut A. Grötz, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066-72.
Kyrgidis
Athanassios
A
Teleioudis
Zisis
Z
Vahtsevanos
Konstantinos
K
D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D004164:Diphosphonates / Q000009:adverse effects*; D018450:Disease Progression; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D007571:Jaw Diseases / Q000139:chemically induced* / Q000453:epidemiology*; D008297:Male; D010020:Osteonecrosis / Q000139:chemically induced* / Q000453:epidemiology*; D015995:Prevalence; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012307:Risk Factors; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid